Impact of denosumab on bone mass in cancer patients

Ursa Brown-Glaberman, Alison T StopeckUniversity of Arizona Cancer Center, Tucson, AZ, USAAbstract: Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brown-Glaberman U, Stopeck AT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/78823999925b406a81c169e57d1323fd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:78823999925b406a81c169e57d1323fd
record_format	dspace
spelling	oai:doaj.org-article:78823999925b406a81c169e57d1323fd2021-12-02T08:53:02ZImpact of denosumab on bone mass in cancer patients1179-1438https://doaj.org/article/78823999925b406a81c169e57d1323fd2013-07-01T00:00:00Zhttp://www.dovepress.com/impact-of-denosumab-on-bone-mass-in-cancer-patients-a13568https://doaj.org/toc/1179-1438Ursa Brown-Glaberman, Alison T StopeckUniversity of Arizona Cancer Center, Tucson, AZ, USAAbstract: Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life expectancies. Whereas oral bisphosphonates remain the most commonly used therapeutic option for CTIBL, additional treatment options may be required for patients who do not respond adequately or are intolerant to bisphosphonates, have renal insufficiency, or are receiving treatment with nephrotoxic medications. For these patients, denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor-κB ligand (RANKL), offers an effective and well-tolerated alternative. Several recent randomized trials have examined the use of denosumab as treatment for CTIBL associated with hormone ablation therapy for breast and prostate cancer. Recent data suggest a possible role for RANKL inhibitors in both chemoprevention and the prevention of cancer recurrence through direct effects on breast tissue and breast cancer stem cells. The outcomes of several international Phase III clinical trials currently underway will help clarify the role of denosumab in patients undergoing cancer therapy.Keywords: denosumab, osteoporosis, osteopenia, hormone ablation therapy, cancer therapy-induced bone loss, chemotherapyBrown-Glaberman UStopeck ATDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Issue 1, Pp 117-129 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Brown-Glaberman U Stopeck AT Impact of denosumab on bone mass in cancer patients
description	Ursa Brown-Glaberman, Alison T StopeckUniversity of Arizona Cancer Center, Tucson, AZ, USAAbstract: Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life expectancies. Whereas oral bisphosphonates remain the most commonly used therapeutic option for CTIBL, additional treatment options may be required for patients who do not respond adequately or are intolerant to bisphosphonates, have renal insufficiency, or are receiving treatment with nephrotoxic medications. For these patients, denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor-κB ligand (RANKL), offers an effective and well-tolerated alternative. Several recent randomized trials have examined the use of denosumab as treatment for CTIBL associated with hormone ablation therapy for breast and prostate cancer. Recent data suggest a possible role for RANKL inhibitors in both chemoprevention and the prevention of cancer recurrence through direct effects on breast tissue and breast cancer stem cells. The outcomes of several international Phase III clinical trials currently underway will help clarify the role of denosumab in patients undergoing cancer therapy.Keywords: denosumab, osteoporosis, osteopenia, hormone ablation therapy, cancer therapy-induced bone loss, chemotherapy
format	article
author	Brown-Glaberman U Stopeck AT
author_facet	Brown-Glaberman U Stopeck AT
author_sort	Brown-Glaberman U
title	Impact of denosumab on bone mass in cancer patients
title_short	Impact of denosumab on bone mass in cancer patients
title_full	Impact of denosumab on bone mass in cancer patients
title_fullStr	Impact of denosumab on bone mass in cancer patients
title_full_unstemmed	Impact of denosumab on bone mass in cancer patients
title_sort	impact of denosumab on bone mass in cancer patients
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/78823999925b406a81c169e57d1323fd
work_keys_str_mv	AT brownglabermanu impactofdenosumabonbonemassincancerpatients AT stopeckat impactofdenosumabonbonemassincancerpatients
_version_	1718398310837911552

Impact of denosumab on bone mass in cancer patients

Ejemplares similares